X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

LBPH

Closed

Longboard Pharmaceuticals Inc

59.98
0.00 (0.00%)
Last Update: 13 Dec 2024 17:30:00
Yesterday: 59.98
Day's Range: 59.98 - 59.98
Send
When Written:
 
5.11
Longboard Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological diseases. The company was founded in 2018 and is headquartered in Morrisville, North Carolina. Longboard's lead product candidate, LP352, is a small molecule inhibitor of the enzyme phosphodiesterase 4 (PDE4) that is being developed for the treatment of Fragile X Syndrome (FXS). FXS is a genetic disorder that causes intellectual disability, behavioral and emotional problems, and other symptoms. LP352 has demonstrated promising results in preclinical studies and is currently being evaluated in a Phase 1 clinical trial. Longboard is also developing other PDE4 inhibitors for the treatment of other neurological disorders, such as Alzheimer's disease and schizophrenia. The company is backed by leading healthcare investors and has partnerships with academic institutions and other biopharmaceutical companies.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X